Fairweather M, et al. - For patients with metastatic gastrointestinal stromal tumors (GISTs) treated with tyrosine kinase inhibitors (TKIs) and surgery, treatment recommendations were refined. Determination of progression-free survival (PFS) and overall survival (OS) from time of surgery and from start of initial TKI was performed among all patients undergoing GIST metastasectomy between 2001 and 2014 at 2 institutions. Outcomes suggest that in the absence of multifocal progressive disease, surgery in metastatic GIST patients on imatinib is correlated with outcomes at least comparable with second-line sunitinib and may be considered in select patients.